To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To assess pharmacokinetic properties of rCD4 in humans. To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and AIDS related complex (ARC).

Condition	Treatment or Intervention	Phase
HIV Infections	Drug: CD4 Antigens	Phase I

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patients must have:

• HIV-1 seropositivity.
• Diagnosis of AIDS or AIDS related complex (ARC).
• Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy.
• The ability to sign a written informed consent form prior to treatment.
• A willingness to abstain from all other experimental therapy for HIV infection during the entire study period.
• A life expectancy of at least 3 months.

Exclusion Criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded:

• Serious active opportunistic infections.
• Malignancies other than Kaposi's sarcoma.

Concurrent Medication: Excluded:

• Zidovudine (AZT).
• Corticosteroids.
• Nonsteroidal anti-inflammatory agents (NSAI).
• Other experimental therapy.

Patients with the following are excluded:

• Serious active opportunistic infections.
• Malignancies other than Kaposi's sarcoma.

Prior Medication: Excluded within 3 weeks of study entry:

• Zidovudine (AZT).
• Chemotherapy.
• Immunomodulators.
• Other experimental therapy.

California
      Genentech Inc, South San Francisco,  California,  94080,  United States

Study ID Numbers:  064A; CO030g; Serial Number 002
Record last reviewed:  January 1990
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002004
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08